# The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

> **NCT01081834** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 678 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Canagliflozin
- **DRUG:** Placebo
- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT01081834
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-08
- **Final completion:** 2012-03
- **Target enrollment:** 678 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01081834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01081834, "The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01081834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*